| Affimed N.V. | $5,000 | Affimed will apply its proprietary Redirected Optimized Cell Killing (ROCK®) platform, which enables the generation of both NK cell and T cell-engaging antibodies, to discover and advance innate immune cell engager-based immunotherapeutics of interest to Genentech. | Genentech (Roche Group) | Collaboration | Germany |
| K2M Group Holdings | $1,400 | The combined business will have a competitive portfolio across Stryker's Spine product categories and leverage a more powerful commercial engine. | Stryker | Acquisition | United States |
| Mologen AG | $1,160 | In the co-development agreement, the companies aim to finalize the IMPALA study, gain an opportunity to fully realize the potential of lefitolimod in combination with other immuno-oncology drugs and in additional indications outside the colorectal cancer maintenance setting. Success in additional indications would bring in additional milestones and royalties representing substantial value for MOLOGEN. | Oncologie, Inc. | Commercialization Agreement | Germany |
| BeiGene | $903 | BeiGene intends to use net proceeds from the Offering for clinical trials, preparation for registration filings, and for the launch and commercialization of its core product candidates (zanubrutinib, tislelizumab, and pamiparib). | Morgan Stanley & Co. International plc | IPO | China |
| Ziylo | $800 | Ziylo's glucose binding molecules are synthetic molecules designed by Professor Anthony Davis at the University of Bristol. The combination of this technology with state-of-the-art insulin engineering pioneered by Novo Nordisk aspires to realise the world's first glucose responsive insulin and transform the treatment of diabetes. | Novo Nordisk | Acquisition | United Kingdom |
| Adapt Pharma | $735 | The acquisition of Adapt Pharma adds NARCAN Nasal Spray to Emergent’s portfolio of only-in-class products with applications in both government and commercial markets. NARCAN Nasal Spray became commercially available in early 2016 after receiving FDA approval in November 2015. | Emergent BioSolutions Inc. | Acquisition | United States |
| Illumina, Inc. | $650 | Illumina intends to use the net proceeds of the offering to repurchase approximately $102.7 million of its common stock | Undisclosed | Senior Notes Offering | United States |
| argenx | $625 | ARGX-115 employs argenx’s SIMPLE Antibody™ technology and binds specifically to the protein glycoprotein A repetitions predominant (GARP), which plays a key role in the regulation of production and release of active transforming growth factor beta (TGF-?beta). | AbbVie Inc | Option Agreement | Belgium |
| Genea IVF | $509 | The 31-year-old Sydney-based Genea provides reproductive technology services including infertility, in-vitro fertilization (IVF) and other assisted conception treatment. The company developed technology including culture media and embryo transfer catheters is currently applied in more than 600 clinics across 60 countries. | WeDoctor (Weiyi Group) | Acquisition | Australia |
| BioNTech AG | $425 | BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. | Pfizer Inc. | Collaboration | United States |
| JW Pharmaceutical | $402 | LEO Pharma will obtain exclusive rights to develop and commercialize JW1601 - an innovative new drug candidate which has a dual mechanism of action that blocks the activation and migration of the immune cells that cause atopic dermatitis by selectively acting on the histamine H4 receptor and inhibiting the histamine signaling that causes itching. | LEO Pharma | Out-licensing Agreement | Korea |
| Oscar Health | $375 | When seniors in the US turn 65, they can choose to be part of either traditional Medicare or Medicare Advantage, which is operated through private insurers like Oscar and often provides additional healthcare benefits. | Verily Life Sciences,Capital G Venture Capital | Investment | United States |
| Sichuan Kelun-Biotech Biopharmaceutical (Kelun Pharmaceutical Group) | $350 | A167 is an anti-PD-L1 monoclonal antibody in Phase 2 clinical trials discovered and developed by Kelun-Biotech in China, with potential to treat multiple solid tumor and hematological cancers. | Harbour Antibodies BV | Partnership | China |
| Greater Pacific Capital | $300 | From the first fund, GPC had invested in several companies, including in Edelweiss Financial Services Ltd and Torrent Pharma Ltd. “The plan is to have a corpus of $1 billion to deploy in India. This would include some commitments from LPs as well who want to co-invest in deal opportunities along with the fund,” an executive said. | Undisclosed | Investment | United Kingdom |
| Chinese Diagnostics Medical Corporation | $293 | Chinese Diagnostics Medical Corporation specializes in the design and development of diagnostic testing reagents. Its products include biochemical, chemiluminescence, radioactive reagents. | Legend Capital | Private Equity | China |
| Biotest USA (Biotest Pharmaceuticals Corporation) | $286 | BPC will continue to operate as Biotest Pharmaceuticals Corporationuntil all FDA regulatory approvals have been obtained. The plasma collected at Biotest Plasma Centers is used to manufacture critical care therapies that treat life threatening disorders in a variety of therapeutic areas. | Grifols Shared Services North America, Inc. | Acquisition | United States |
| PaxVax | $270 | This acquisition will broaden Emergent’s development pipeline with the addition of a next generation adenovirus 4/7 vaccine candidate which is intended to meet the government’s stated requirement of protecting the U.S. military against common causes of acute respiratory disease. | Emergent BioSolutions | Acquisition | United States |
| Medall Healthcare | $212 | This will be the largest investment in an Indian diagnostics company to date. As of the date of this announcement, subject to closing, Constellation is expected to be the only India-focused healthcare services company to be publicly listed outside of India. | Constellation Alpha Capital | Acquisition | India |
| Gilead Sciences | $198 | Momelotinib has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a potentially differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive spleen and constitutional symptom control. | Sierra Oncology | Asset Acquisition | United States |
| Rakuten Aspyrian | $150 | The financing will also support manufacturing scale-up for the commercialization of ASP-1929 and corporate growth including the initial buildup of commercial operations to support the launch of ASP-1929 in the United States, Japan and Europe. | Hiroshi Mikitani (Rakuten Inc.) | Series C Financing | United States |
| Ironshore Pharmaceuticals & Development, Inc. | $143 | With the FDA approval of JORNAY PM™ in hand, Ironshore's primary focus has shifted to ensuring its optimal commercial launch which is the only stimulant medication that is dosed once daily in the evening for patients with Attention Deficit Hyperactivity Disorder. | Undisclosed | Private Placement | Cayman Islands |
| F. Hoffmann-La Roche Ltd. | $127 | Through this licensing agreement, GBT will develop and commercialize inclacumab, a novel fully human monoclonal antibody against P-selectin. GBT also plans to develop inclacumab as a treatment for vaso-occlusive crises (VOC) in patients with sickle cell disease (SCD). | Global Blood Therapeutics, Inc. | Licensing Agreement | Switzerland |
| Glenmark Pharmaceuticals | $120 | Harbour BioMed will lead the clinical development and commercialization of GBR 1302, with the option to manufacture GBR 1302 for the Greater China market. GBR 1302, Glenmark's lead immuno-oncology candidate, works by stimulating the patient's immune system against HER2 overexpressing tumor cells. | Harbour Antibodies BV | Licensing Agreement | India |
| Quethera Limited | $110.5 | Quethera is a gene therapy company headquartered in the United Kingdom focused on ocular disorders like glaucoma. Through this transaction, Astellas has acquired Quethera's ophthalmic gene therapy program, which uses a recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes to treat glaucoma. | Astellas Pharma | Acquisition | United Kingdom |
| Aralez Pharmaceuticals Inc. | $110 | Nuvo would acquire Aralez's Canadian specialty pharmaceutical business, formerly known as Tribute Pharmaceuticals Canada Inc. which includes Cambia®, BlextenTM, SuvexxTM (sold as Treximet® in the USA), as well as the Canadian distribution rights to Resultz,®. | Nuvo Pharmaceuticals Inc., Deerfield Management Company | Acquisition | Canada |
| Tempus | $110 | Tempus is in partnership with the American Society of Clinical Oncologists (ASCO), leading academic medical centers and NCI designated cancer centers, hospital networks and community physicians across the United States. | T. Rowe Price, Revolution Growth | Series E Financing | United States |
| TOT BIOPHARM Company Limited | $102 | TOT BIOPHARM focuses on the R&D, manufacturing and marketing of high-end anti-tumor drugs. The company now has over 10 drugs in the R&D stage, including three biologics and three small molecules, which have received investigational new drug application (IND) approvals, as well as one antibody-drug conjugate (ADC), which is expected to receive approval soon. | China Universal (Cayman) GP Limited | Series B Financing | China |
| Dongpu Pharmaceutical | $102 | "This round of financing will accelerate the development of our key pipelines. Dongpu will seize the opportunity of China's anti-tumor drug market to grow at a high speed. In the future, it will also take advantage of its existing industrial chain platform to expand its multi-directional direction. Multi-level international links and cooperation make the benefits of resource integration more significant." | Yuanda Financial Holdings Group | Series B Financing | China |
| bluebird bio, Inc. | $100 | The collaborators will specifically leverage Regeneron's VelociSuite® platform discovering and characterising fully human antibodies & T cell receptors (TCRs) directed against tumor-specific proteins and peptides. The collaborators have jointly selected six initial targets and will equally share the R&D costs. | Regeneron Pharmaceuticals, Inc. | Commercialization Agreement | United States |
| Ambys Medicines | $100 | Ambys is pioneering the application of cell and gene therapies, and gain-of-function drug therapy, to frame restorative liver treatments and preventative therapeutics to address multiple liver diseases that are untreatable or poorly treated today. | Takeda Pharmaceutical Company Limited | Partnership | United States |
| Dermavant (Roivant Sciences) | $100 | Roivant announced that NovaQuest Capital Management has made a $100 million strategic investment in Dermavant in exchange for conditional milestone payments achieved by tapinarof, a Phase 3-ready investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) for the treatment of psoriasis and atopic dermatitis. | NovaQuest Capital Management | Investment | United States |
| Arvinas | $100 | Arvinas focuses on developing a new class of drugs based on protein degradation. At its most basic, this involves attaching a molecule to an unwanted protein, bringing it to the attention of the cell’s garbage disposal, the proteasome. | Undisclosed | IPO | United States |
| Solids Launch facility | $99 | This new Solids Launch facility will focus on development activities for drugs in tablet form and manufacture them for worldwide market launches. | Boehringer Ingelheim | Manufacturing Investment | Germany |
| TraceLink | $93 | This investment will fuel the digitalization of the global pharmaceutical supply chain through the integration of real-time information-sharing, in order to create a highly predictable supply chain for the industry. | Georgian Partners | Investment | United States |
| Glenmark Pharmaceuticals | $91.1 | Glenmark’s orthopaedic and pain management business, valued at Rs. 635 cr., will be transferred to a new entity to-be incorporated by True North. New entity wouldnbe named as ‘Integrace Private Limited’. Integrace will market the product portfolio in India and Nepal. | True North Capital | Collaboration | India |
| Harbour BioMed | $85 | Harbour BioMed has integrated its proprietary Harbour Mice technologies into its newly built antibody technology and discovery biology, preclinical and clinical development operations and entered into multiple license and collaboration agreements for Harbour Mice. | GIC Private Limited | Series B Financing | China |
| Artios Pharma | $84 | Artios is actively developing a pipeline of highly promising first-in-class DDR therapies identified from a global network of leading researchers in the DDR field, including through Cancer Research UK. | Andera Partners | Series B Financing | United Kingdom |
| Can-Fite BioPharma Ltd | $75 | The main aim of the agreement includes the commercialization of Can-Fite’s Piclidenoson for the treatment of rheumatoid arthritis and psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). | CMS Medical (China Medical System Holdings Limited) | Distribution Agreement | Israel |
| SQZ Biotechnologies | $72 | Proceeds from the financing support SQZ's most advanced programs in solid tumors and auto-immunity. The Company's lead program in antigen presenting cells (APCs) for oncology will have its first application in multiple HPV+ tumor indications; future applications will address solid tumors across cancer types. | Illumina Ventures | Series C Financing | United States |
| SalvaRx Limited (SalvaRx Group plc) | $71.7 | SalvaRx's strategy is to invest in a portfolio of companies involved in novel cancer immunotherapies and develop them up to clinical proof of concept. SalvaRx's management team have a proven track record of discovering and commercialising drugs in the area of cancer immunotherapy with Bristol-Myers Squibb and Johnson & Johnson. | Portage Biotech | Acquisition | United Kingdom |
| Synergy Pharmaceuticals Inc. | $68 | The Agreement grants exclusive rights to Luoxin to develop and commercialize Synergy’s lead product TRULANCE® (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in mainland China, Hong Kong and Macau. | Luoxin Pharmaceutical Group Co., Ltd. | Licensing Agreement | United States |
| Ambys Medicines | $60 | Ambys Medicines is pursuing multiple strategies to develop innovative new medicines for patients suffering from chronic liver diseases, including cell therapy for hepatocyte transplantation, gene therapy for liver regeneration, and drug therapy to replace lost protein function. | Third Rock Ventures | Series A Financing | United States |
| Therachon AG | $60 | Therachon plans to use the proceeds to advance the company’s lead pipeline candidate TA-46, a novel protein therapeutic for achondroplasia, the most common form of disproportionate short stature in humans, as well as to support the expansion of its rare disease pipeline. | Novo Holdings | Mezzanine Financing | Switzerland |
| Apexigen, Inc. | $58 | Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for oncology with lead product APX005M - a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. | 3E Bioventures Capital | Series C Financing | United States |
| BioCryst Pharmaceuticals | $57.5 | BioCryst expects to use the net proceeds of this offering for general corporate purposes, which may include, but are not limited to, funding worldwide development, manufacturing, regulatory and commercial activities for the prophylactic and acute BCX7353 programs, focusing primarily on the United States, European Union and Japan; the advancement of development activities of our fibrodysplasia ossificans progressiva (“FOP”) and other preclinical rare disease program; post-approval commitments for | Undisclosed | IPO | United States |
| ReViral | $55 | The new funding will enable ReViral to progress its lead drug candidate (RV521), a highly potent and orally bioavailable potential treatment for RSV infections, into Phase IIa paediatric and adult trials, and to continue the development of a novel series of antiviral inhibitors targeting RSV replication. RV521 is soon expected to enter an international multicentre Phase IIa paediatric trial. | New Leaf Venture Partners | Series B Financing | United Kingdom |
| Jacobio Pharmaceuticals | $55 | Jacobio’s lead drug, JAB-3068, inhibits PTPN11, an enzyme believed to play a role in several blood cancers. | Qiming Capital | Series C Financing | China |
| Acer Therapeutics | $46 | Acer intends to use the net proceeds from this offering to fund its research and development efforts, to seek regulatory approval for EDSIVO™, to invest in pre-commercial activities for EDSIVO™, to advance development of ACER-001, to acquire or in-license product candidates, and for general corporate purposes, including working capital and other general and administrative purposes. | Roth Capital Partners | IPO | United States |
| Cipla Quality Chemical Industries | $45.2 | The drug maker, majority-owned by India’s pharmaceutical giant Cipla, makes a range of drugs including antiretrovirals, anti-malaria and Hepatitis B and C drugs which it sells mostly in sub-Saharan African countries. Cipla, according to a statement, will still maintain a majority stake even after the IPO . | | IPO | Uganda |
| BioTime | $43 | Juvenescence management, through their previous roles in pharmaceutical companies with marketed products, have taken multiple products to commercialization with annual peak sales aggregating well over $70 billion. Juvenescence has, in its short existence, already sourced and created a pipeline of exciting therapeutic candidates, all of which have the potential to positively modify aging. | AgeX Therapeutics, Juvenescence Limited | Alignment Agreement | United States |
| Vernalis plc | $43 | The acquisition of Vernalis would provide Ligand with a portfolio of more than 8 fully-funded partnered programs, or shots on goal, including programs in the respiratory, oncology and Central Nervous System areas. | Ligand Pharmaceuticals Incorporated | Acquisition | United Kingdom |
| Karuna Pharmaceuticals | $42 | Karuna plans to use the proceeds from the financing to advance its lead product candidate, KarXT (Karuna-xanomeline-trospium chloride), including the initiation of a Phase 2 trial in patients with schizophrenia in the third quarter of 2018 and the expansion into other therapeutic areas, including a non-opiate pain indication. | ARCH Venture Partners | Series A Financing | United States |
| Editas Medicine | $40 | The joint collaboration reinforces both Allergan's and Editas' continued commitment to developing innovative treatments for unmet needs in eye care. EDIT-101 is Editas Medicine's experimental CRISPR genome editing medicine for the treatment of Leber Congenital Amaurosis type 10 (LCA10). | Allergan plc | Option Exercise | United States |
| Vaccinex | $40 | Vaccinex intends to use the net proceeds of this offering to fund its ongoing development of certain therapies, to repay certain debt obligations, to fund continued preclinical research discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. | Oppenheimer Holdings | IPO | United States |
| Profectus BioSciences, Emergent BioSolutions | $36 | The grant funding by CEPI is for the purpose of advancing the development and manufacture of a vaccine against the Lassa virus—an estimated 100,000 to 300,000 cases of Lassa virus infection occur each year. | Coalition for Epidemic Preparedness Innovations (CEPI) | Grants & Awards | United States |
| Big Beat Challenge | $35 | Unveiled at this year’s European Society of Cardiology Congress in Munich, the £30 million award will be one of the largest and most ambitious of its kind; a challenge to scientists, clinicians, innovators and entrepreneurs to look beyond incremental gains and accelerate breakthroughs that could transform lives across the globe. | British Heart Foundation | Grants & Awards | United Kingdom |
| Recombinetics | $34 | Proceeds will be used to accelerate new research and development by adding scientists and expertise focused on emerging science, including regenerative medicine; to continue to add to our robust intellectual property and patent portfolio; expand the laboratory, animal care and advanced reproductive facilities; and build out the business development, product marketing and management team to take advantage of licensing and co-development opportunities. | Gundersen Health | Series A Financing | United States |
| Dubai Science Park Generics Manufacturing Facility | $34 | The custom-built factory is the first advanced manufacturing facility to be opened in Dubai Science Park and is equipped with the latest European technology, meeting stringent global regulatory standards, the company said in a statement. Pharmax said it will produce medications targeting chronic conditions common in the Middle East and other developed markets, including cardiovascular diseases, psychiatric and neurological disorders. | Pharmax Pharmaceuticals | Manufacturing Investment | United Arab Emirates |
| KaNDy Therapeutics | $32 | The proceeds will enable KaNDy Therapeutics to advance its breakthrough non-hormonal drug candidate, NT-814, for treatment of multiple symptoms of the menopause, through a multi-country Phase 2b dose-ranging study due to start recruiting patients in Q4 2018 with headline results expected in late 2019. | Longitude Capital | Series C Financing | United Kingdom |
| Magnolia Neurosciences Corporation | $31 | Magnolia Neurosciences Corporation is a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines. | Accelerator Life Science Partners | Series A Financing | United States |
| IMPACT Therapeutics | $30 | The proceeds from the series C will be used for the clinical development of IMP4297, a potential best-in-class PARP inhibitor, and to advance IMPACT's integrated programs targeting DNA Damage Response (DDR). | Decheng Capital, Lilly Asian Ventures | Series C Financing | China |
| Lacerta Therapeutics | $30 | The Lacerta relationship expands Sarepta’s gene therapy pipeline to up to 11 unique candidates focused on CNS gene therapy targets. Lacerta will manage the majority of pre-clinical development while Sarepta will lead clinical development and commercialization. Sarepta will owe development and sales-based milestones to Lacerta and pay single-digit royalties on net sales. | Sarepta Therapeutics | Licensing Agreement | United States |
| Lacerta Therapeutics (UF Innovate) | $30 | Lacerta is a clinical-stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. | Sarepta Therapeutics | Licensing Agreement | United States |
| OvaScience, Millendo Therapeutics | $30 | OvaScience will merge with Millendo in an all-stock transaction. The merged company will focus on advancing Millendo’s pipeline of distinct and transformative treatments for orphan endocrine diseases. Upon shareholder approval, the combined company is expected to operate under the name Millendo Therapeutics | New Enterprise Associates | Merger Agreement, Investment | United States |
| Genome Protection, Inc. (Cleveland Biolabs, Everon BioSciences) | $30 | GPI signed a Simple Agreement for Future Equity (SAFE) with Norma Investments. GPI's goal is to develop and commercialize drugs for anti-aging applications capable of prolonging human health and life-span. GPI granted Norma the right to purchase shares of GPI's capital stock in exchange for the payment of up to $30 million, of which $10.5 million was paid shortly after the execution of the SAFE. | Norma Investments Limited | Joint Venture, Equity Agreement | United States |
| Gritstone Oncology | $30 | Gritstone Oncology will leverage its proprietary EDGE™ artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell receptors (TCRs) directed to selected targets for use in bluebird bio’s established cell therapy platforms. | bluebird bio, Inc. | Series C Financing | United States |
| Reata Pharmaceuticals | $30 | The payment was received following the initiation of AYAME, a Phase 3 clinical trial to assess the efficacy and safety of bardoxolone methyl (bardoxolone) for the treatment of diabetic kidney disease in Japan. Bardoxolone is an experimental, oral, once-daily activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. | Kyowa Hakko Kirin | Milestone Payment | United States |
| Aridis Pharmaceuticals | $26 | Aridis Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. | Maxim Group LLC | IPO | United States |
| RedHill Biopharma | $25 | The Company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund clinical development programs, including preparations for a second Phase III study with RHB-104 for Crohn’s disease, initiation of a pivotal Phase III study with RHB-204 for NTM, for commercial operations including TALICIA® (H. pylori) launch preparations | Ladenburg Thalmann Financial Services | IPO | Israel |
| Mammoth Biosciences | $23 | Mammoth is exploring the use for CRISPR as the search engine for biology. The CRISPR-Cas complexes are fitted with a guide-RNA, which tells them what specific sequence to look for in the DNA or RNA sample. | Mayfield Partners | Series A Financing | United States |
| Windlass Healthcare Private Limited (WHPL) | $22.2 | Windlas Healthcare has a robust manufacturing infrastructure with a USFDA inspected oral solids manufacturing facility. WHPL also has a dedicated R&D facility for formulations development and has developed four First-to-File ANDAs in the last two years. The strategic deal allows Cadila Healthcare to expand its existing manufacturing base. The cost of acquisition is Rs. 155.55 crore and the deal will be completed by the end of September 2018. | Cadila Healthcare Ltd | Acquisition | India |
| Protagonist Therapeutics | $22 | Protagonist Therapeutics is a clinical stage biopharmaceutical company discovering and developing novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-100 is an oral alpha-4-beta-7 integrin antagonist peptide that is under evaluation for potential treatment of inflammatory bowel diseases. Proceeds from the financing will be used to advance development of drug candidate PTG-100. | BVF Partners L.P. | Equity Financing | United States |
| Exicure | $22 | Exicure expects to use the proceeds from this offering for advancing the development of Exicure’s drug candidates - AST-008 - an SNA consisting of toll-like receptor 9 (TLR9) agonists designed for immuno-oncology applications; XCUR17 - an antisense SNA that targets the mRNA encoding IL-17RA, an essential initiation protein. | Sphera Global Healthcare | Private Placement | United States |
| Depomed, Inc. | $20 | Products covered by the Royalty Agreement and amendment include Glumetza® and its authorized generic, Jentadueto XR®, Invokamet XR® and Synjardy XR®. | PDL BioPharma, Inc. | Royalty Agreement | United States |
| Forbius (Formation Biologics) | $18.8 | The new CPRIT grant award follows a successful completion of an AVID100 Phase 1 clinical trial. The grant will support operations and Phase 2a development of AVID100, a highly potent anti-EGFR antibody-drug conjugate, in three cancer indications with significant unmet medical need. | Cancer Prevention and Research Institute | Grants & Awards | United States |
| Akcea Therapeutics (Ionis Pharmaceuticals) | $18 | TEGSEDITM (inotersen), a product of Ionis' proprietary antisense technology, is an antisense oligonucleotide (ASO) inhibitor of human transthyretin (TTR) production and was developed by Ionis. WAYLIVRATM, a product of Ionis' proprietary antisense technology, is under regulatory review in the U.S., E.U. and Canada as a treatment for familial chylomicronemia syndrome (FCS). | PTC Therapeutics, Inc. | Licensing Agreement | United States |
| Lenus Therapeutics (GtreeBNT) | $17.8 | EB is a rare genetic disease that most often appears in the skin, although it can also affect internal organs. There are currently no medications approved for the treatment of EB. RGN-137, a topical gel initially developed by RegeneRx Biopharmaceuticals, Inc., is the one of the only late stage treatment candidates and currently the subject of clinical trials in the United States. | RegeneRx Biopharmaceuticals, Inc. | Joint Venture | South Korea |
| Pharmaxis | $17.3 | The funds raised will be used to strengthen the Pharmaxis balance sheet as the Company conducts partnering negotiations for its clinical development program into Lysyl Oxidase 2 Inhibitors (LOXL2) expected to occur in 2H18. The company will have a A$54m pro?forma cash balance (30 June 2018 post raising). In addition, the funds will be used to further invest in pre?clinical programs and general working capital. | Arix Biosciences | Private Placement | Australia |
| BioNano Genomics | $16 | The biotech would raise about $16 million at the midpoint of the range. | Roth Capital Partners | IPO | United States |
| Apexigen | $15 | Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for oncology with lead product APX005M - a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M and the Company’s additional preclinical programs were discovered using APXiMAB™, Apexigen’s proprietary product discovery platform. | Decheng Capital | Series B Financing | United States |
| EdiGene | $15 | EdiGene Inc leverages its proprietary platforms to develop gene-editing therapies for a wide range of diseases, and to conduct high-throughput genome screening to enable dissection of functional big data in biological contexts. | Lilly Asia Ventures | Series pre-B Financing | China |
| Genomics plc | $13.6 | Scientists from Vertex and Genomics will work closely together to incorporate their deep understanding of human genetics into research and development related to target discovery and target validation in certain diseases. Both companies will also have the opportunity to suggest additional diseases for the collaboration, where human genetic evidence may be particularly powerful. | Vertex Pharmaceuticals Incorporated | Equity Financing | United Kingdom |
| ContraVir Pharmaceuticals | $13 | ContraVir previously announced it is ready to initiate the dosing of HBV patients in a dose-ranging study with an optimized formulation of TXL™ to allow for more efficient, predictable and precise delivery while reducing drug burden and maintaining consistent efficacy. The objective of the next clinical trial with TXL™ will be to characterize the pharmacokinetic profile of the new formulation in HBV patients and to select the target dose to be advanced into Phase 3. | Maxim Group | Financing | United States |
| Akili Interactive | $13 | Akili’s digital medicines embed specific stimuli, designed to engage targeted areas of the brain, into immersive action video game experiences to treat medical conditions across neurology and psychiatry. Akili’s lead digital treatment in development, AKL-T01 in pediatric ADHD, is now under review by the FDA. | CLSA | Additional Series C Financing | United States |
| Blueberry Therapeutics | $12.8 | Blueberry Therapeutics will use the net proceeds of the Series B Fundraising to fund its development programme for BB2603 for the treatment of onychomycosis and tinea pedis, as well as progressing its earlier stage acne, topical analgesia and atopic dermatitis programmes. | China Medical System Holdings | Series B Financing | United Kingdom |
| AxiaMed | $12.4 | AxiaMed’s Payment Fusion platform has become the healthcare industry’s preferred SaaS-based payment platform and is used by hundreds of hospitals and thousands of ambulatory providers. Payment Fusion enables healthcare software vendors to integrate secure payment technology into their applications, lessening the risks of payment data breaches, and reducing compliance burdens while improving the financial performance of providers by expanding payment options available to patients. | Health Enterprise Partners | Capital Investment | United States |
| American Cancer Society | $10 | The new funding will be raised to support cancer patient services programs, breakthrough research, and cancer prevention efforts, including tobacco control. According to the American Cancer Society, almost 30 percent of cancer deaths this year will be caused by cigarette smoking. | CVS Health | Fundraising | United States |
| Washington University School of Medicine in St. Louis | $10 | The partnership will fund projects based on competitive review by a governance committee composed of leaders from both institutions. Mallinckrodt plans to fund two types of grants while also supporting direct collaboration with Washington University School of Medicine, guided by a joint steering committee with representatives from both parties. | Mallinckrodt | Collaboration | United States |
| Citius Pharmaceuticals | $10 | The gross proceeds of the Offering are expected to be approximately $10.0 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. Citius intends to use the net proceeds from this Offering for general corporate purposes, including its Phase 3 clinical Mino-Lok trial for the treatment of catheter related bloodstream infections and its Phase 2b clinical trial of Hydro-Lido cream for the treatment of hemorrhoids, and working capital and capital expenditure | H.C. Wainwright & Co. | IPO | United States |
| Pneuma Respiratory | $10 | Haisco Pharmaceutical Group will receive the rights to distribute the pharmaceutical products of Pneuma Respiratory in China. Haisco will be responsible for financing the regulatory records of China. | Haisco Pharmaceutical Group | Distribution Agreement | United States |
| Mobilize AZ | $10 | With BCBSAZ investing $10 million over three years, the initiative will support prevention, treatment, and recovery programs to help providers and local organizations fight against the opioid epidemic. Mobilize AZ includes tailored strategies to including a grant program that will award a minimum of $1 million each year to community organizations involved in education, treatment, and recovery from opioid misuse. | Blue Cross Blue Shield | Investment | United States |
| SAB Biotherapeutics | $10 | SAB’s unique immunotherapy platform is the only one in the world to produce human polyclonal antibodies—the natural way to fight disease—on a commercial scale without using humans. SAB expects to enter two new Phase 1 and 2 trials during the next 18 months for severe hospitalized influenza and MERS-CoV respectively | T. Denny Sanford (Sanford Health System) | Series A Financing | United States |
| VolitionRx Limited | $9 | As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. | Undisclosed | Private Placement | Belgium |
| Human Cell Atlas | $9 | Wellcome is committing £7 million to the Human Cell Atlas, a global endeavour to map every single cell type in the human body. The £7m in new funding will enable the UK researchers to generate data from millions of human cells, towards the aim of creating a reference map of every single cell type in the human body. | Wellcome Sanger Institute | Grants & Awards | United Kingdom |
| Bugworks Research | $9 | Bugworks' novel bacterial topoisomerase inhibitor (NBTI) is highly effective against a very broad spectrum of multi-drug resistant bacterial pathogens. This potent first-in-class antibiotic was designed using ELUDE, Bugworks' proprietary efflux-pump avoidance platform. | University of Tokyo Edge Capital (UTEC) Japan | Series A Financing | United States |
| Ampio Pharmaceuticals | $8 | Ampio intends to use the net proceeds from this offering for continued preclinical development of Ampion and funding an Ampion clinical trial, if required. | | IPO | United States |
| Sempre Health | $8 | Sempre Health's innovative and dynamic discount programs enable health plans to financially align members with broader clinical priorities by allowing them to pay less for filling their prescriptions on time. Proceeds will be used to further build out Sempre's two-sided network of payers and pharma manufacturers. | Social Capital | Series A Financing | United States |
| Angiochem | $7.5 | With this latest financing, the company is on track to further develop ANG1005. This compound has already delivered promising results and now, we are gearing up for a pivotal Phase 3 trial that will hopefully lead to a long awaited therapeutic solution for patients with breast cancer who suffer from brain metastases and leptomeningeal carcinomatosis | Undisclosed | Series C Financing | Canada |
| Modulus Discovery | $7.2 | Modulus will use the proceeds to accelerate its drug discovery research through leveraging the company’s proprietary computational platform and efficient virtual pharma operating model. | Fast Track Initiative, Inc. | Series A Financing | Japan |
| RootPath | $7 | The company was launched in 2017 by life sciences venture capital and incubation firm Nest.Bio. RootPath will use its proceeds to advance its immuno-oncology programs and obtain key data on accuracy, efficacy and safety in animal models. Founded by scientists and bioengineers instrumental in the development of synthetic biology, gene editing and single-cell sequencing technologies, RootPath continues to build on the collective expertise and insights from its founders, Drs. Xi Chen, Le Cong, Yinq | Sequoia China | Seed Financing | United States |
| University of British Columbia | $6.5 | Genomics Application Partnership Program (GAPP), which supports university-industry collaborations to bridge the gap between basic research and commercialization. In this partnership program, AbCellera will apply its microfluidic single-cell platform to the discovery and engineering of large panels of antibodies against three novel targets. Lead candidates from the discovered antibodies will be selected by UBC and then functionally tested in genetically modified animal models. | AbCellera Biologics, Genome Canada | Partnership | Canada |
| National Disease Research Interchange (NDRI) | $6.5 | A unique element of NDRI’s work supported through this agreement is provision and distribution for neurological research through the National Institute of Neurological Disorders and Stroke (NINDS). In the last five years, NDRI has provided 884 neurological biospecimens to 79 researchers, including normal and pathological tissues representative of 20 distinct diseases, including ALS, Alzheimer’s disease, Parkinson’s disease, muscular dystrophy, pure autonomic failure, Lewy body dementia, and spin | National Institutes of Health (NIH) | Grants & Awards | United States |
| Novaremed AG | $6.2 | The proceeds of the financing will be used to prepare for a global Phase 2b clinical study of its lead compound, NRD.E1, a novel, first-in-class, small molecule for patients suffering from diabetic neuropathic pain (DNP). Together with CHF 4.44 million raised in April 2018, the company will be well capitalized to prepare for a global Phase 2b clinical study, which is expected to be initiated in H2 2019. | Undisclosed | Financing | Israel |
| DSM Biomedical | $6 | Aerie will immediately have a worldwide exclusive license for all ophthalmic indications to DSM’s polyesteramide polymer technology for an unlimited number of compounds. Aerie and DSM will continue collaborative research activities including the transfer of DSM’s formulation technology. Aerie will gain access to DSM’s preclinical stage latanoprost implant with the potential for initial clinical studies in glaucoma patients in 2019. | Aerie Pharmaceuticals, Inc. | Option Agreement | The Netherlands |
| AVEO Pharmaceuticals | $5.7 | The net proceeds of the offering are expected to be used for working capital and general corporate purposes, including development and pre-commercial expenses incurred in connection with the ongoing Phase 3 clinical trial of tivozanib in the third-line treatment of patients with advanced renal cell carcinoma (“aRCC”) as well as the ongoing Phase 1b/2 clinical trial of tivozanib in combination with OPDIVO® (nivolumab). | Piper Jaffray & Co. | IPO | United States |
| Lunaphore Technologies SA | $5.5 | The funding will be used to enhance the market launch and drive market adoption of the first Lunaphore products*, a precision medicine solution that performs ultra-rapid immunostainings and holds the potential to improve patient outcomes. | Occident Group | Series B Financing | Switzerland |
| DURECT Corporation | $5 | DURECT Corporation received a $5 million milestone payment from Indivior PLC triggered by Indivior's approval of the New Drug Application (NDA) for PERSERIS™ (risperidone) in July 2018. Indivior made an upfront non-refundable payment to DURECT of $12.5 million and also agreed to make an additional $5 million payment to DURECT contingent upon NDA approval of PERSERIS, which occurred in July 2018. | Indivior PLC | Milestone Payment | United States |
| Nebula Genomics | $4.3 | The funds will support the company’s mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data | Khosla Ventures | Seed Financing | United States |
| Forge Therapeutics | $4 | Forge Therapeutics' CARB-X pipeline includes Forge's LpxC antibiotic and continues to expand with new mechanisms of action, new treatment modalities and increased funding. CARB-X is the world's largest public-private partnership accelerating early development antibacterial research and development. CARB-X is investing more than $500M to support innovative antibiotics and is supported by its partners around the globe including BARDA, NIH, Wellcome Trust, California Life Science Institute, RTI, | Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) | Grants & Awards | United States |
| Agenus | $4 | Merck initiated a Phase I clinical trial of an undisclosed antibody candidate discovered by Agenus, under the two companies license and research collaboration. | Merck & Co. | Milestone Payment | United States |
| ApoGen Biotechnologies | $4 | The company intends to use the funding from the expanded Series A to hire additional staff and establish a laboratory in Seattle. ApoGen is initially focusing its drug development efforts on an antiviral component of the human innate immune system, the APOBEC cytidine deaminases, which have been implicated as a prominent source of mutations in cancers. | Merck Ventures BV | Series A Financing | United States |
| Children's Hospital of Philadelphia, NeuroVive Pharmaceutical AB | $4 | The extensive program evaluating preclinical efficacy and exploring viable future clinical endpoints for the NVP015 program. The studies under the grant from the U.S. Department of Defense CDMRP will be the third, and most extensive, collaboration between NeuroVive and CHOP. | Department of Defense, Office of the Congressionally Directed Medical Research Programs (CDMRP) | Grants & Awards | United States |
| BioBeats | $3.1 | BioBeats creates evidence-based wellbeing products that help transform people’s lives for the better. Through harnessing user data, artificial intelligence, and human insight, BioBeats provides an ever-improving cycle of evidence-based interventions, finding patterns that link stress to health risks and physical outcomes. | Oxford Sciences Innovation | Fundraising | United States |
| Curation of Real World Data for Rare Disease Research (RDMD) | $3 | “RDMD was born out of my own personal journey with a rare disease called neurofibromatosis type 2, a disease that affects only 1 in 30,000 people,” said Onno Faber, RDMD founder, chairman and head of product. RDMD aims to partner with rare disease biopharmaceutical companies to provide deep clinical electronic health record (EHR) data from patients, rare disease doctors, and foundations. The company’s proprietary database of research-and-regulatory-grade evidence can be leveraged to gain insight | Lux Capital | Seed Funding | United States |
| Revive & Restore Catalyst Science Fund | $3 | The Catalyst Science Fund will invest primarily in proof of concept projects applied toward high impact solutions to conservation challenges. The Catalyst Science Fund will build on the strengths of both organizations, including a network of scientists and conservationists to provide diverse insights into opportunities presented by recent biotech advances, as well as entrepreneurial expertise and perspective to make the most strategic investments to advance the development of the field. | Promega Corporation | Grants & Awards | United States |
| Capillary Biomedical | $2.9 | CapBio has developed the SteadiSettm infusion set with SteadiFlowtm technology, a patented design that addresses several key failure points with current infusion sets that dramatically affect the health, quality of life, and cost for the 1.2 million worldwide insulin pump users. | Cove Fund | Seed Financing | United States |
| Almac Discovery, Elasmogen | $2.6 | The £2M peer reviewed collaborative project entitled ‘A Technology Platform for Next Generation VNAR based Oncology Medicines’, plans to utilise the highly selective, high affinity and yet low molecular weight non-antibody VNAR protein scaffold and build a versatile platform to facilitate the discovery and development of targeted oncology therapeutics. | Innovate UK | Grants & Awards | United Kingdom |
| rqmicro AG | $2.6 | A key factor to assure the safety of drinking and industrial water is the detection of dangerous pathogenic bacteria such as Legionella bacteria, which pose an emerging threat to public health. This financial support accelerates the development and market launch of a revolutionary solution for the rapid detection of more pathogenic microorganisms. | European Commission | Grants & Awards | Switzerland |
| Agilvax | $2.3 | AX09 is being developed as an immunotherapeutic agent for the treatment of TNBC by inhibiting the function of xCT - a biomarker associated with tumor growth and metastatic progression. The grant will provide up to $2.3 million in funding for preclinical studies, cGMP manufacturing and a nonclinical toxicology study that will enable an investigational new drug application (IND) submission for Agilvax’s lead immunotherapy product, AX09. | National Cancer Institute | Grants & Awards | United States |
| Marshall Health | $2 | With a $2 million grant from the Foundation payable over four years, the System is an innovative, comprehensive approach that aims to reduce opioid overdoses and overdose deaths, improve access to substance abuse prevention and treatment services, and help reduce the rising rates of HIV and hepatitis C infections. | Merck Foundation | Grants & Awards | United States |
| Phico Therapeutics | $1.9 | Phico is developing SASPject PT3.8, an antibacterial therapy for the systemic treatment of severe Pseudomonas aeruginosa (P. aeruginosa) infections with a high mortality rate. As clinical trials are expanded, it is anticipated that the product will also be used in situations where a P. aeruginosa infection is suspected but yet to be confirmed, further extending the market opportunity for SASPject PT3.8. | Innovate UK | Grants & Awards | United Kingdom |
| PURE Bioscience | $1.5 | PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products primarily based on silver dihydrogen citrate, or SDC - is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. | Undisclosed | Private Placement | United States |
| EyePoint Pharmaceuticals | $1.35 | EyePoint Pharmaceuticals is a specialty biopharmaceutical company developing and commercializing innovative ophthalmic products for serious eye disorders. | Undisclosed | IPO | United States |
| University of North Carolina Wilmington (UNCW), Alcami Corporation | $1.1 | "Partnership for Workforce Development in the Biopharmaceutical Industry" is a comprehensive laboratory, lecture, and internship series approved by NIIMBL's Project Call 1.0 that address biomanufacturing technology and workforce development issues. NIIMBL's governing committee chose the Alcami-UNCW proposal for its thorough, well-qualified, and innovative approach to workforce development. | National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) | Grants & Awards | United States |
| Titan Pharmaceuticals | $1.1 | The loan, if made (the "Convertible Loan"), will convert automatically into shares of Titan common stock upon the issuance by the EMA of marketing approval for Probuphine at a conversion price per share equal to the lower of (i) the closing price on the loan funding date and (ii) the closing price on the conversion date. In the event the EMA has not granted marketing approval by December 31, 2019, the Convertible Loan will become due and payable, together with accrued interest at the rate of o | L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. | Amendment | United States |
| DermaXon | $0.99 | Along with help by the universities, DermaXon worked with skincare company Rodan + Fields and Galderma and MD Anderson Cancer Center, where they were able to learn more about how other substances and medications affect the brain, such as oral medications and cannabinoids found in cannabis. | Montana Board of Research and Commercialization Technology (MBRCT) | Grants & Awards | United States |
| Bioasis Technologies | $0.7 | As previously disclosed, the net proceeds from the private placement will be used to support ongoing research and development, clinical development, manufacturing and other activities in respect of the Company’s clinical development pipeline based on developing the xB3 TM platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders. | Undisclosed | Private Placement | Canada |
| HealthFin | $0.50 | Healthfin, which offers financial assistance to patients who do not have medical insurance or those who are under-insured, will use the funds for tech upgrades and hiring. | Sprout Venture Partners | Series A Financing | India |
| Indee Labs | $0.37 | This preclinical study will pave the way for biopharmaceutical companies to transition away from using viruses. The aim is to enable gene-modified cell therapy manufacturing with open source biology to provide patients with improved access to curative therapies for blood cancer. | NSW Medical Device Fund | Grants & Awards | United States |
| Advanced Proteome Therapeutics Corporation | $0.3 | Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells. Advanced Proteome is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential. | Undisclosed | Private Placement | Canada |
| Mor Research Applications (Clalit Health Services) | $0.3 | Under the strategic alliance agreement with Mor, FSD Pharma and SciCann will execute a series of rigorous, randomized, placebo-controlled clinical studies to demonstrate the safety and efficacy of these products, in order to bring to market advanced and innovative cannabinoid-based products that are backed up by solid clinical data achieved through the highest standards of rigorous and objective clinical research typical for the development process of pharmaceutical products. | FSD Pharma, SciCann Therapeutics | Collaboration | Israel |
| CoreBiome | $0.2 | CoreBiome has licensed technology from the University of Minnesota for synthetic DNA standards, which are used as controls for quality assurance in the microbiome sequencing process. | Clinical and Translational Science Institute - University of Minnesota | Grants & Awards | United States |
| Albumedix | Undisclosed | Novartis will evaluate molecules in combination with Albumedix´s engineered albumin variants for enhanced delivery. Beyond the modulation of pharmacokinetic profiles, the potential for novel routes of administration and mechanisms of action will be assessed across multiple therapeutic areas. | Novartis Pharma AG | Collaboration | United Kingdom |
| BioNTech AG | Undisclosed | Following the completion of successful process evaluations involving leading fill-/finish-machine manufacturers, SMP and BioNTech want to explore and develop superior packaging as well as application devices manufactured by SMP for a range of BioNTech products. | SiO2 Medical Products, Inc. | Partnership | Belgium |
| Fraunhofer IME | Undisclosed | This Licensing Agreement allows LenioBio to utilize Fraunhofer's proprietary vector solution and technology for the cryopreservation of cell lysates. | LenioBio GmbH | Licensing Agreement | Germany |
| AMRI | Undisclosed | The agreement will capitalize on AMRI’s process chemistry expertise in the synthesis and formulation of Nemus’ proprietary prodrug of tetrahydrocannabinol (THC). This molecule forms the basis of NB1111, Nemus’ compound in development for the treatment of glaucoma. | Nemus Bioscience | Development Agreement | United Kingdom |
| Qiagen N.V. | Undisclosed | QIAGEN’s Day-One Lab Readiness initiative with SRL includes strategic planning for market access to companion diagnostics, filing for reimbursement, and alignment of medical communication by SRL, QIAGEN and pharmaceutical partners. | SRL, Inc. | Collaboration | The Netherlands |
| Lineage Biosciences | Undisclosed | Lineage Biosciences, a Palo Alto-based start-up, was founded based on technology for the profiling of antibody responses using next-generation sequencing of immunoglobulin genes (Ig-SEQ). Ig-SEQ enables deep analysis of antibodies generated by natural immune responses during infection, autoimmune disease, cancer, immunization, and vaccination. | AbCellera Biologics | Acquisition | United States |
| D. Western Therapeutics Institute (DWTI) | Undisclosed | Glaukos and DWTI will conduct joint research for the development of novel intraocular products for the treatment of glaucoma using compounds from DWTI’s proprietary ROCK inhibitor compound library, one of DWTI’s fundamental technologies, and potentially design and synthesize new compounds for this collaboration. Glaukos will conduct the evaluation and development of the compounds. | Glaukos Corporation | Development Agreement | Japan |
| Advantia Health | Undisclosed | Through its partnership with Elligo, Advantia’s health care practices will be able to join Elligo’s Research Ready™ network, offer their patients access to clinical research as a care option and enroll them into studies. As a result, patients will have access to state-of-the-art treatments closer to home and remain under the care of their trusted physician. | Elligo Health Research | Partnership | United States |
| Science Exchange | Undisclosed | Reveal’s AI-based tissue analysis utilizes trained pathology models to recognize disease patterns in whole slide digital images. This service can be applied to tumor profiling, quantitative immunohistochemistry, NASH, toxicology and quantitative multiplexing. | Reveal Biosciences | Partnership | United States |
| Charcot-Marie-Tooth Association (CMTA) | Undisclosed | This collaboration with the Charcot-Marie-Tooth Association aims to validate the role of HDAC6 in multiple forms of Charcot-Marie-Tooth (CMT) disease and evaluate the efficacy ofricolinostat, a selective HDAC6 inhibitor, in animal models. | Regenacy Pharmaceuticals | Collaboration | United States |
| Sectra | Undisclosed | Sectra PACS is optimized for high production environments and designed to shorten report turnaround times, enhance result distribution workflows, and improve communication between radiology and referring departments. For five continuous years in the US, Sectra PACS has won the customer satisfaction award 'Best in KLAS' for large hospitals. | Stanford Health Care | Contract Agreement | United States |
| Rfxcel Corporation | Undisclosed | The alliance was created to implement and support new compliance management and serialisation processing software to ensure full compliance with current and future international legislative requirements ahead of the 2019 EU Falsified Medicines Directive (FMD) deadline. | Abdi Ibrahim | Compliance Agreement | United Kingdom |
| Oncologie, Inc. | Undisclosed | Through the partnership, the companies agreed to partner on the development of biomarkers associated with Oncologie’s Immuno-oncology pipeline. | HTG Molecular Diagnostics, Inc. | Partnership | China |
| Andor Pharmaceuticals | Undisclosed | Andor's pending Abbreviated New Drug Application (ANDA) of Methylphenidate included all bioequivalence metrics recommended by FDA and is expected to be approved as an AB-rated generic equivalent to the brand Concerta®. Under the agreement, Lannett will primarily provide sales, marketing and distribution support of Andor's Methylphenidate ER product, for which it will receive a percentage of the net profits. | Lannett Company | Licensing Agreement | United States |
| Cedars-Sinai Medical Center | Undisclosed | Under the terms of the agreement, the lab of world-renowned microbiome researcher Mark Pimentel, M.D., executive director of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai Medical Center, will focus on the discovery of new therapeutic treatments related to conditions of the gut microbiome. Dr. Pimentel has played an integral role in advancing science's understanding of the gut microbiome including his widely-accepted research on a methanogen as an agent for causi | Salix Pharmaceuticals (Bausch Health Companies) | Collaboration | United States |
| Yale University School of Medicine | Undisclosed | This is an ongoing multi-year collaboration with Yale’s Division of Neurocognition, Neurocomputation, and Neurogenetics (N3) on the neurobiological basis of dysregulated mood and behavior in humans. BlackThorn is licensing GEMINI-DOT (Gene Expression Mapping Integrated with Neuro-Imaging for Discovery Of Therapeutics) - which can bi-directionally map gene expression patterns and neuroimaging features to optimize the selection of drug targets and clinical populations. | BlackThorn Therapeutics | Licensing Agreement | United States |
| Antares Pharma, Inc. | Undisclosed | The aim of the Agreement is to develop a combination drug device rescue pen which will utilize the Antares QuickShot® auto injector and an undisclosed Pfizer drug. | Pfizer Inc. | Development Agreement | United States |
| Cystic Fibrosis Gene Therapy Consortium, Oxford BioMedica, Imperial Innovations | Undisclosed | The new collaboration is a joint initiative of Boehringer Ingelheim’s Respiratory Therapeutic Area and Research Beyond Borders (RBB) in which it has received an option to license the exclusive global rights to develop, manufacture, register, and commercialise this lentiviral vector-based gene therapy for the treatment of cystic fibrosis. Boehringer Ingelheim will provide its multinational industry expertise, including a rich heritage in the respiratory field, to drive the product towards the cli | Boehringer Ingelheim | Partnership | United Kingdom |
| The University of Texas MD Anderson Cancer Center | Undisclosed | The joint effort brings together MD Anderson's translational medicine and clinical research capabilities with Jazz's hematology/oncology portfolio. The initial focus of the collaboration is to evaluate and generate additional data for Vyxeos® (daunorubicin and cytarabine) liposome for injection, in new patient populations and in combination with other therapies. | Jazz Pharmaceuticals | Collaboration | United States |
| Nordion Medical Isotopes (Sotera Health) | Undisclosed | With the sale, BWXT now owns Nordion’s former medical isotopes business, including the radiochemical and contract manufacturing operations in Kanata, Ontario, and the isotope production facility in Vancouver, British Columbia | BWX Technologies | Divestment | United States |
| California Cryobank, Cord Blood Registry | Undisclosed | Recognized as the world’s premier donor sperm and donor egg bank, California Cryobank has been an industry leader and innovator since 1977. GI Partners combined California Cryobank and CBR under the California Cryobank Life Sciences platform, bringing together best-in-class organizations to provide enhanced domestic and international expansion opportunities in both the donor reproductive tissue and newborn stem cell industries. | GI Partners | Merger Agreement, Investment | United States |
| Selvita S.A. | Undisclosed | MEN1703/SEL24 is a first-in-class orally available dual PIM/FLT3 kinase inhibitor with a unique activity profile currently investigated for the treatment of AML and with preclinical data suggesting potential activity in other hematological malignancies and solid tumors. | Menarini Ricerche (Menarini Group) | Clinical Sponsorship | Poland |
| Oxford Genetics | Undisclosed | Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has secured a multi-million pound contract with a leading multi-billion dollar global ecommerce provider of reagents and tools to the research and clinical community. | Undisclosed | Supply Agreement | United Kingdom |
| CertiRx Corporation “Verinetics” | Undisclosed | ACG Inspections is looking forward to implementing an add-on security layer to provide Multi-Factor Authentication to the end consumer. Falsified medications are one of the major problems faced by the global pharmaceutical industry. Verinetics patent-protected software product, TraxSecur™ is a next-generatio n solution for detecting and deterring fraud in the supply chain. | ACG Inspection | Partnership | United States |
| Ausway Pharmaceutical | Undisclosed | Ausway specialises in the supply and distribution of vitamins and dietary supplements both in Australia and overseas with a particular emphasis on its e-commerce platform which sells directly into China. Ausway currently generates revenues in excess of $18 million with positive earnings. | Star Combo Pharma Limited | Acquisition | Australia |
| Gibraltar Laboratories | Undisclosed | Gibraltar Laboratories is a leading outsourced provider of microbiology and analytical chemistry testing for pharmaceutical and medical device manufacturers. “In addition to its testing expertise, Gibraltar’s facilities are located in the Northeast pharmaceutical corridor, home to many of the top pharmaceutical manufacturers in the United States, "said Michael B. Petras Jr., CEO of Sotera Health. | Sotera Health | Acquisition | United States |
| Prescription Pharmaceuticals Business | Undisclosed | Perrigo's Prescription Pharmaceuticals (Rx) business serves patients and health systems with 'extended topicals' medications, to treat ailments at more affordable prices. The differentiated and diversified portfolio includes topical generic medicines in multiple dosage forms, including creams, foams, mousses, gels, liquids and inhalable products. | Perrigo Company plc | Re-organization | Ireland |
| Maricopa Integrated Health System | Undisclosed | “This agreement strengthens Trans-Hit Bio’s presence in the USA and is a valuable addition to our worldwide network of academic and hospital-based biobanks for sourcing high-grade biospecimens. We take great pleasure in working with the MIHS team who is very motivated, knowledgeable and professional, as they are also well versed to Good Clinical Practices,” said Dr. Pascal Puchois, Chief Executive Officer at Trans-Hit Bio. | Trans-Hit Bio | Commercialization Agreement | United States |
| Astarte Biologics | Undisclosed | Memphis-based Key has established itself as a trusted supplier of critical raw materials, specifically human cells used in fundamental research, cell therapy manufacturing and process development, and commercial immunotherapies. Astarte brings highly complementary immunology expertise that will play a valuable role in expanding the combined company’s cell characterization, custom cell line and assay development capabilities. With the merger the company now has footprints in both Memphis and Sea | Ampersand Capital Partners, Key Biologics | Merger Agreement, Investment | United States |
| Perrigo Company plc | Undisclosed | Perrigo holds exclusive rights to market, sell, and distribute a non-prescription version of Nasonex® OTC in the United States following Perrigo's receipt of all necessary regulatory approvals. Nasonex® is currently available by prescription only. Annual prescription brand and generic market sales for the 12 months ending June 2018 were approximately $214 million as measured by IQVIA. | Merck & Co, Inc. | Licensing Agreement | Ireland |
| Showcase | Undisclosed | The Company’s Apeaz® drug continues to be in demand in both the United States and Canadian markets as a arthritis pain relief medicine. | Innovus Pharmaceuticals | Purchase Agreement | Canada |
| Florida Pharmaceutical Products, Inc. | Undisclosed | Florida Pharmaceutical Products, Inc., focuses on improving patient outcomes with generic medications spanning a broad therapeutic range. Investments fund research to identify new treatments and guiding strong product candidates through the development lifecycle. | Woodfield Distribution, LLC | Acquisition | United States |
| St. Jude Children’s Research Hospital | Undisclosed | The Agreement is for developing a first-in-class ex vivo lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency (X-SCID). X-SCID is the most common form of SCID, affecting approximately one in 50,000 to 100,000 newborns worldwide. The therapy includes a low dose of busulfan prior to reinfusion of the patients’ own gene-modified blood stem cells. | Mustang Bio (Fortress Biotech) | Licensing Agreement | United States |
| Baylor College of Medicine | Undisclosed | VistaGen and Baylor are collaborating on a first-step study with healthy volunteer Veterans to test potential anti-suicidal effects of VistaGen’s AV-101. AV-101 is an oral, non-opioid, non-sedating NMDA receptor glycine B (NMDAR GlyB) antagonist that offers the potential to be a new at-home treatment for multiple CNS indications with high unmet medical need. | VistaGen Therapeutics, Inc. | Collaboration | United States |
| TheLeukemia & Lymphoma Society | Undisclosed | The Company is partnering with TheLeukemia & Lymphoma Society to develop STRO-001, Sutro’s CD74-targeting antibody-drug conjugate, to treat relapsed and/or refractory multiple myeloma and non-Hodgkin’s lymphoma. Sutro intends to use the funding for a Phase 1 study, initiated in April of this year, to evaluate STRO-001 for treating multiple myeloma, diffuse large B-cell lymphoma, mantle cell lymphoma andindolent lymphomas, such asfollicular lymphoma | Sutro Biopharma | Partnership | United States |
| Desert Oasis Healthcare | Undisclosed | Through a value-based contract, Desert Oasis Healthcare joins a select group of health systems in the U.S. who use Digital Medicines to focus on improving outcomes in high-risk patients. Proteus has conducted several clinical studies demonstrating the clinical and economic benefits of using Digital Medicines to improve outcomes in these patients, including a successful randomized control trial in patients with uncontrolled hypertension and type 2 diabetes | Proteus Digital Health | Contract Agreement | United States |
| Psyadon Pharmaceuticals | Undisclosed | Ecopipam is a potent, selective antagonist of the human D1 receptor family being developed for the treatment of pediatric TS. TS is a childhood-onset neurodevelopmental condition, characterized by motor and vocal tics, for which there exists an unmet need for new therapies. | Emalex Biosciences (Paragon Biosciences) | Acquisition | United States |
| Haplogen GmbH, Evotec AG | Undisclosed | The goal of the research alliance is to develop new antiviral compounds addressing the high unmet medical need in reducing COPD exacerbations. | Bayer AG | Collaboration | Austria |
| Napa Therapeutics | Undisclosed | Napa Therapeutics is based on groundbreaking research in NAD metabolism conducted in the lab of Eric Verdin, MD, President and CEO of the Buck Institute. The Verdin lab will collaborate with Napa, using Insilico's drug development engine to speed the discovery of new compounds. | The Buck Institute for Research on Aging, Insilico Medicine, Juvenescence Ltd | Launch | United Kingdom |
| Ubiquigent Limited | Undisclosed | This latest grant and investment provides additional support for the advancement of one of our key programmes. The programme is now well underway, and we look forward to reaching our endpoint of developing novel compounds in this disease area much sooner than originally planned. The team is now even better placed to support our existing and new partners focused on ubiquitin system drug discovery. | IP Group plc, Innovate UK | Grants & Awards | United Kingdom |
| SNBL U.S.A. | Undisclosed | This acquisition will add comprehensive preclinical safety testing services to Altasciences’ current full-service clinical and bioanalytical offerings. Altasciences will now support all crucial steps in early-stage drug development, from lead candidate selection to proof of concept. | Altasciences | Acquisition | United States |
| Shanghai Model Organisms Center (GCOS) | Undisclosed | GCOS leverages the expertise of several gene editing technologies to develop conventional knockout (KO), conditional KO, transgenic knock-in and humanized models. These capabilities are now exclusively available to CrownBio's global customers for custom model generation, selection, IVF, rapid expansion and re-derivation. | Crown Bioscience | Alliance | China |
| Helsinn Group | Undisclosed | ALOXI® (palonosetron hydrochloride), a 5-HT3 receptor antagonist was approved in Vietnam. Mundipharma consistently delivers high-quality medicines while standing by the values it represents. Its mission is to alleviate the suffering of patients and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthc | Mundipharma GmbH | Licensing Agreement | Switzerland |
| US Oncology Research | Undisclosed | The collaboration is based on the PANOVA-3 trial which is a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with nab-paclitaxel and gemcitabine in patients with unresectable locally advanced pancreatic cancer. | Novocure | Collaboration | United States |
| Karolinska Institutet | Undisclosed | This collaboration will explore RXi's sd-rxRNA compounds against targets involved in T cell and NK cell differentiation and/or in the immune cell tumor-induced stress response with the aim of producing anti-tumor adoptive cell therapy grafts with improved functionality and persistence. | RXi Pharmaceuticals Corporation | Collaboration | Sweden |
| Fox Chase Cancer Center | Undisclosed | The Partnership focuses on the study will use Natera's proprietary customized assay and next-generation sequencing (NGS)-based technology to determine whether Signatera (RUO) can be used to distinguish between the recurring and non-recurring kidney cancer cases. | Natera | Collaboration | United States |
| Stratford Pharmaceuticals | Undisclosed | The acquisition of Stratford fits into Eli's strategy to enter the global animal health industry. Stratford currently provides a wide arrangement of dermatology products to over 10,000 veterinary hospitals in the US and 8 other countries. Stratford will continue to operate independently under the leadership of its Founder and CEO Brian Nugent out of its Oldsmar, FL corporate headquarters. | Eli Global | Acquisition | United States |
| Escape Therapeutics | Undisclosed | The Company plans to utilize the technology in conjunction with its pluripotent stem cell platform for applications in regenerative medicine. The initial priority of the agreement will be to utilize the technology in advancing our two lead programs AGEX-BAT1 and AGEX-VASC1 for age-related metabolic and vascular disease respectively. | AgeX Therapeutics (BioTime, Inc.) | Patent Acquisition | United States |
| Viscogliosi Brothers | Undisclosed | "This transaction allows Ember to continue to focus on our exciting late stage osteoarthritis (OA) program which offers the potential of addressing the actual cause of this debilitating disease by regrowing cartilage in the knee. The previously commercialized OP-1 product portfolio had at one point generated approximately $100M in annual revenues for Stryker and had been viewed as a formidable competitor to Medtronic's Infuse. | Ember Therapeutics | Divestment | United States |
| Cyclica | Undisclosed | Through a multi-phase collaboration, WuXi will leverage and evaluate Cyclica’s cloud-based proteome Ligand Express™ screening platform to investigate the off-target profiles of small molecules, apply Cyclica’s novel and proprietary advanced AI technology to create state of the art predictive models for ADMET properties, and support the testing and optimization of Cyclica’s next generation AI-based de novo drug design technology. | WuXi AppTec Research Service Division | Collaboration | Canada |
| Healthy Interactions | Undisclosed | Map4health is designed as a platform to help improve the quality of diabetes patient support in between in-person coaching sessions by enabling patients to connect with educators through text and video-chat, as well as providing weekly digital activities to sustain patient engagement. | Merck | Platform Launch | United States |
| Tolero Pharmaceuticals (Sumitomo Dainippon Pharma) | Undisclosed | The clinical collaboration aims for exploring the potential of combination therapy with AbbVie's venetoclax and Tolero's investigational agent, alvocidib, for the treatment of relapsed/refractory acute myeloid leukemia (AML). | AbbVie Inc | Clinical Collaboration | United States |
| OHSU School of Medicine | Undisclosed | Supported by funding from JDRF, the leading global organization funding type 1 diabetes (T1D) research, OHSU is conducting a Phase 1 single-center, randomized, three-way, controlled, crossover clinical study to test the efficacy of a new closed-loop algorithm for managing blood glucose in people with T1D before and after exercise. | Xeris Pharmaceuticals | Commercialization Agreement | United States |
| Invicro (Konica Minolta Company) | Undisclosed | EBG will be responsible for providing data from their affiliate companies; Cerveau Technologies, Inc. and Meilleur Technologies, Inc.; novel Tau tracer (MK-6240) and Amyloid tracer (NAV-4694); respectively. Both parties will utilize the AmyloidIQ and TauIQ platforms to provide the pharmaceutical industry access to improved informatics and analytics capabilities together with a more streamlined approach to supporting neurodegenerative disease modifying therapy development. | Enigma Biomedical Group | Collaboration | United States |
| Anthem, Inc | Undisclosed | The Anthem-Walmart program, launching in January 2019, will enable consumers who are enrolled in Anthem’s affiliated Medicare Advantage (MA) plans. The new collaboration is expected to improve access to these items while significantly reducing the out-of-pocket costs for those enrolled in Anthem’s affiliated MA plans. | Walmart | Collaboration | United States |
| Jerome Stevens Pharmaceuticals | Undisclosed | With more than 120 million prescriptions per year, Levothyroxine is the most prescribed drug in the United States, and we see exciting opportunities to grow market share, given the evolving market dynamics in the manufacturing and validation challenges associated with this product. | Amneal Pharmaceuticals | Supply Agreement | United States |
| Citation Clinical Labeling Systems | Undisclosed | Citation provides clinical trial labels for pharmaceutical and biotechnology companies, clinical research organizations, and clinical packagers. This acquisition strengthens AWT’s commitment to the global healthcare labeling market and will allow AWT to take advantage of growth opportunities in the clinical trial label markets. | AWT Labels and Packaging | Acquisition | United States |
| Merck | Undisclosed | The collaborators aim to evaluate the combination of Rexahn's RX-5902 and Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 2 trial in patients with metastatic triple negative breast cancer (TNBC). The clinical trial evaluate the safety and efficacy of the combination of RX-5902 and KEYTRUDA in patients with metastatic TNBC who have progressed following at least one prior treatment. | Rexahn Pharmaceuticals | Clinical Collaboration | United States |
| Centre for the Commercialization of Antibodies and Biologics (CCAB) | Undisclosed | The initiative merges CCAB’s business acumen with its research and technical expertise to support the co-development of new biological therapeutics and build viable companies around ImmunoBiochem’s novel breast cancer therapeutic candidate. ImmunoBiochem is developing novel potentiated biologics to treat triple-negative breast cancer (TNBC), an aggressive form of breast cancer for which there are currently no targeted biological treatment options. | ImmunoBiochem | Co-development Agreement | Canada |
| Rexahn Pharmaceuticals | Undisclosed | The Collaboration Agreement is based on the aim to evaluate the combination of Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 2 trial in patients with metastatic triple negative breast cancer (TNBC). | Merck & Co. | Clinical Collaboration | United States |
| Medigene AG | Undisclosed | In this research collaboration, Medigene will supply Structured Immunity with a lead TCR candidate for a high-profile solid tumor target. Structured Immunity will evaluate the TCR's specificity and recognition properties using their established structural immunology technologies. | Structured Immunity | Collaboration | Germany |
| Primity Bio | Undisclosed | Primity Bio is a leading provider of cutting-edge flow cytometry services with deep expertise in assay development, early drug discovery, pre-clinical animal sample analysis, biomarker discovery, and advanced human clinical sample analysis. Using the latest in single-cell analysis technologies, Primity specializes in highly complex immunophenotyping, intracellular signaling, cell sorting (FACS), and high-parameter CyTOF (mass cytometry) analysis. | Caprion Biosciences | Acquisition | United States |
| TrialAssure | Undisclosed | TrialAssure will provide a software-as-a-service (SaaS) solution to Otsuka, allowing their internal disclosure experts the ability to use proven reporting tools, built-in validation, the ability to integrate with their master data system, and the ability to retool core data for application to multiple registries, meeting global reporting requirements for ClinicalTrials.gov, EudraCT, and other global registries. | Otsuka Pharmaceutical | Partnership | United States |
| Science Exchange | Undisclosed | Taconic recently added an innovative Easi-CRISPR technology to its gene-modifying toolkit by acquiring a worldwide, non-exclusive license from the University of Nebraska. Leveraging the most comprehensive model generation toolkit, Taconic employs all major gene-editing technologies including homologous recombination, pronuclear injection (PNI), shRNAi, CRISPR, and Easi-CRISPR. | Taconic Biosciences | Collaboration | United States |
| Evotec AG | Undisclosed | Evotec will apply its drug discovery platform, especially in ligand-based design, to seek to design novel, safe and efficacious products to address diabetes and associated morbidities. Once suitable pre-clinical candidates are selected, Novo Nordisk will use Evotec’s INDiGO platform to move through pre-clinical studies to enter IND registration. | Novo Nordisk | Alliance | Germany |
| Exact Sciences Corp. | Undisclosed | Pfizer will join Exact Sciences' sales representatives in reaching both physicians and health systems and will also actively participate in extending and deepening the Cologuard marketing campaign. | Pfizer Inc. | Co-promotion Agreement | United States |
| National Institute for Biotechnology in the Negev (NIBN) | Undisclosed | The Companies collaborated with National Institute for Biotechnology, Negev to develop and commercialize a novel alginate scaffold technology for cell transplantation, with an initial focus on autoimmune diseases. | Orgenesis Inc., BGN Technologies | Licensing Agreement | Israel |
| Amarex Clinical Research | Undisclosed | In celiac disease, larazotide is the only drug which has successfully met its primary endpoint with statistical significance in a Phase 2b efficacy clinical trial (342 patients). Amarex will provide Innovate with electronic data capture solutions and associated services for data management and biostatistics to Innovate Biopharma to support Amarex's Phase 3 trial. | Innovate Biopharmaceuticals, Inc. | Contract Agreement | United States |
| Bradley Martin, University of Arkansas for Medical Sciences (UAMS) | Undisclosed | In acquiring the Opioid Risk Prediction Tool, TrestleTree also has developed a preventive approach to combating opioid abuse and addiction, specifically by combining the tool’s predictive modeling capability with the company’s unique and proven behavior change model. | TrestleTree (Harvard Pilgrim) | Intellectual Property Rights Agreement | United States |
| US Oncology Research | Undisclosed | By capturing genomic and clinical data from all ethnicities, ages, genders, and from patients with co-morbidities, the FLEX database provides valuable opportunities to accelerate breast cancer research. It will also enable researchers to investigate the differences and trends between sub-groups and, importantly, to focus on smaller, more diverse, patient populations. | Agendia, Inc. | Clinical Collaboration | United States |
| CENTOGENE AG | Undisclosed | The collaboration brings together Evotec’s leading induced pluripotent stem cell (“iPSC”) platform and broad drug discovery capabilities with CENTOGENE’s unique medical and genetic insights. Evotec and CENTOGENE initiated the collaboration to develop a strategic high-throughput platform for testing novel small molecules in rare hereditary metabolic diseases. | Evotec AG | Partnership | Germany |
| Panacea Biotec, Natco Pharma | Undisclosed | Azacitidine is a nucleoside metabolic inhibitor indicated for the treatment of patients with the B myelodyplastic syndrome (MDS), Natco has provided the technology for manufacturing Azacitidine to Panacea Biotec's facility located at Baddi, Himachal Pradesh, India. Panacea Biotec will be responsible for manufacture and supply of the product, which will be marketed, sold and distributed by Breckenridge in the U.S. | Breckenridge Pharmaceutical | Manufacturing Agreement | India |
| Undisclosed | Undisclosed | Allergen immunotherapy, a time-tested clinical approach, can reduce or eliminate allergy and asthma symptoms by lowering the levels of specific cellular proteins known as immunoglobulin E (IgE) molecules that activate the immune system and trigger immune responses. Through these partnerships, doctors prescribing Arrayit allergy tests gain access to a portfolio of safe & effective allergy medicines for allergy and asthma patients, including custom immunotherapy products formulated upon review of | Arrayit Corporation | Partnership | United States |
| JS InnoPharm (Shanghai) Ltd | Undisclosed | Through this partnership, both companies will leverage their comprehensive knowledge, broad expertise, drug candidates, and networks in the global development of multiple therapeutics. The Strategia Holdings group currently consists of three biopharmaceutical companies; Spirita Oncology, LLC, Mirata BioPharma, LLC, and Strategia Pharmaceuticals, LLC which will work closely together with JS InnoPharm under the Strategic Partnership Alliance. | Strategia Holdings | Partnership | China |
| Ion Channel Innovations | Undisclosed | Urovant has licensed global rights for the development and commercialization of hMaxi-K from Ion Channel Innovations. Urovant plans to meet with the FDA and initiate a Phase 2 clinical study in 2019 to investigate hMaxi-K as a novel treatment for OAB patients who have not responded to other pharmacological therapies. | Urovant Sciences (Roivant Sciences) | Licensing Agreement | United States |
| ProstaGene | Undisclosed | CytoDyn will acquire substantially all of the assets of ProstaGene, including the transfer or assignment of certain intellectual property rights held by ProstaGene and Dr. Pestell. CytoDyn also confirms that Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., Founder and Chief Executive Officer of ProstaGene, will join CytoDyn as Interim Chief Medical Officer. Upon the closing of the acquisition, which is expected in November, Dr. Pestell will become Chief Medical Officer. | CytoDyn | Acquisition | United States |
| Institute for In Vitro Sciences | Undisclosed | Scientists at BASF and Givaudan have developed the Kinetic Direct Peptide Reactivity Assay (Kinetic DPRA), a non-animal test to predict allergic reactions in the skin known as sensitization. However, the Kinetic DPRA has the potential to go beyond a yes/no answer and predict the potency of a sensitizer, which is required by some regulatory agencies. The validation project, designed by BASF and Givaudan, will be conducted over the course of 2018 | BASF, Givaudan | Collaboration | United States |
| Biopharmaceutical Testing Laboratory | Undisclosed | The new laboratory will complement the existing 800m2 facility and offer the new services for high order structure analysis of biologics, including circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR), extrinsic and intrinsic fluorescence, analytical ultracentrifugation (SV-AUC), size exclusion chromatography with multi-angle light scattering (SEC-MALS), dynamic light scattering (DLS) and differential scanning calorimetry (DSC). | SGS | Research Investment | Switzerland |
| Beactica AB | Undisclosed | The funds raised will accelerate the pipeline development over the coming 12 months. This will include the advancement of Beactica's LSD1 programme through an in vivo proof-of-concept study in glioblastoma, and with studies in other indications to follow. | ALMI Invest | Financing | Sweden |
| Epinomics | Undisclosed | The acquisition will give 10x Genomics ATAC-seq technology and fundamental IP to accelerate discoveries and further research in epigenomics, paving the way for a new understanding of disease, diagnostics and therapeutics. | 10x Genomics | Acquisition | United States |
| Centre for Probe Development and Commercialization (CPDC) | Undisclosed | The agreement enables the supply of ImaginAb’s clinical-phase Positron Emission Tomography (PET) imaging agent Zr-89 IAB22M2C to key global geographies. Zr-89 IAB22M2C is a clinical stage CD8 T Cell imaging agent designed to non-invasively determine changes in CD8+ T cell tumor infiltrates induced by immuno-oncological treatments. This approach has the potential to guide the development of immuno-modulatory agents as well as provide an early assessment of whether a patient responds to such a tre | ImaginAb | Supply Agreement | United States |
| Undisclosed | Undisclosed | Tiotropium Bromide DPI is a generic version of Boehringer Ingelheim’s Spiriva® Handihaler. The product is used in the treatment of chronic obstructive pulmonary disease (COPD). This is the second inhalation product in-licensed by Glenmark for the European market after Fluticasone/Salmeterol dry powder inhaler. | Glenmark Pharmaceuticals | Licensing Agreement | |
| Rfxcel Corporation | Undisclosed | rfxcel's dynamic traceability platform enables companies to protect patients, comply with regulatory mandates and gain visibility into their supply chain. The Minnesota Multistate Contracting Alliance for Pharmacy (MMCAP) is a free, voluntary group purchasing organization for government facilities that provide healthcare services. | Minnesota Multistate Contracting Alliance for Pharmacy (MMCAP) | Contract Agreement | United Kingdom |
| Hesperos | Undisclosed | The AD model will be a three-organ system that includes brain cells (cortical neurons) and functioning liver and blood-brain-barrier constructs, as well as re-circulating blood and cerebral spinal fluid surrogates. This will enable scientists to study the body’s systemic response to any chemical introduced into the model, including how it metabolizes in the liver, and how it penetrates into the brain through the blood-brain barrier. | National Institute on Aging of the National Institutes of Health | Grants & Awards | United States |
| National Institutes for Quantum and Radiological Science and Technology | Undisclosed | This collaborative research project focuses on efficacy evaluation of the compound KPO1143, developed by KinoPharma, to prevent the accumulation of protein called tau (hereafter "tau protein") (*1), which is considered a cause of Alzheimer's disease (AD). | KinoPharma | Collaboration | Japan |
| Alkermes | Undisclosed | VIVITROL® (naltrexone for extended-release injectable suspension) is medication is a non-addictive, once-monthly treatment proven to reduce the risk of relapse in opioid-dependent patients when used with counseling following detoxification. | UPMC Health Plan | Contract Agreement | Ireland |
| University of Indianapolis, Ascend Indiana | Undisclosed | Roche Diagnostics and the University of Indianapolis are partnering to create a custom talent pipeline for biomedical equipment technicians through the newly created Roche Academy. The partnership was co-developed with Ascend Indiana, a Central Indiana Corporate Partnership (CICP) initiative. | Roche Diagnostics | Partnership | United States |
| RxBIO Corp. | Undisclosed | Celling products are designed to collect, process and deliver autologous cells to the patient at the point of care to accelerate the body's natural healing process. The Autologous Regenerative Therapies family of concentration systems recovers a high percentage of nucleated, progenitor and other cells by allowing selection of the cell concentrate from user-defined portions of a centrifuged stack. | Celling Biosciences | Licensing Agreement | United States |
| CHDI Foundation | Undisclosed | Evotec provides CHDI with a full range of research activities and expertise in the neuroscience area, including integrated biology and chemistry supported by compound and library management, target validation, stem cell research, high-content screening, computational chemistry, in vitro pharmacokinetics, proteomics and protein production. | Evotec AG | Collaboration Extension | United States |
| DZS Clinical Services | Undisclosed | Through this acquisition, WDBMD will enable DZS Clinical Services to bolster its full-service CRO capabilities and provide more comprehensive and global services to U.S. companies with coverage in Europe and Japan. | WDB Medical Data (WDB Holdings Co., Ltd.) | Acquisition | United States |
Market Place
